1. Introduction {#sec1}
===============

G-protein-coupled receptors (GPCRs), the largest family of membrane proteins (around 800 in humans), are involved in a variety of biological and pathological processes such as development and proliferation \[[@B1]\], neurological disorders \[[@B2]\], angiogenesis \[[@B3]\], and metabolic disorders \[[@B4]\]. GPCRs transmit molecular information from the extracellular side to the intracellular side of the cell, thus mediating many intracellular responses. Although nearly one half of currently marketed drugs target GPCRs \[[@B5]\], only 10% of these receptors have endogenous ligands \[[@B6]\]. Structurally, all GPCRs share an architecture formed by seven transmembrane (TM) helices connected by extracellular and intracellular loops. GPCRs can recognize structurally diverse ligands ranging from photons to ions, amino acids, small organic molecules, lipids, peptides, or proteins \[[@B7]\].

Due to limitations in the purification and crystallization of GPCRs, until recently only a limited number of three-dimensional (3D) structures of GPCRs have been resolved at high resolution by X-ray crystallography: rhodopsin \[[@B8]\], the *β*-adrenergic receptors (*β* ~2~AR \[[@B9], [@B10]\], *β* ~1~AR \[[@B11]\]), the adenosine A~2A~ receptor \[[@B12]\], and the opioid receptors (*κ* \[[@B13]\], *μ* \[[@B14]\]). The highly conserved general architecture including the TM helical bundle and some universally conserved residues allows predicting the 3D structure of unknown GPCRs by homology modeling, while using a few known GPCR structures as a template \[[@B15]\]. However, great cautions are needed when utilizing the homology-based models for detailed GPCR structural and functional annotations since helix kinks are often different in different receptors. Modeling these subtle distinctions, which is essential for ligand docking and screening, remains a major challenge \[[@B16]\]. In addition, since almost all known GPCR structures have been found in their inactive forms, the homology modeling has shown little power to practically predict the 3D structure of GPCRs in the active forms. It is known that the agonist-bound GPCRs take the active forms, whereas the antagonist-bound or inverse agonist-bound GPCRs take the inactive forms.

Ligand-induced activation of GPCRs results in multiple allosteric conformational changes that propagate throughout the receptor structure, ultimately triggering different signaling cascades \[[@B17]\]. In contrast to inactive states of GPCRs, no crystal structures of active states were available until 2011. Given the absence of experimental structural information, several investigators have applied computational strategies to predict activated models of GPCRs \[[@B18]--[@B22]\]. Therein, it is reported that applying an appropriate long-term molecular dynamics (MD) simulation after homology modeling could predict plausible 3D structures of activated GPCRs in view of the induced fit mechanism \[[@B21], [@B22]\]. However, this approach needs to impose appropriate structural constraints prior to the MD simulation, which requires both the skills and experience of an MD specialist. Moreover, MD simulations on ordinary personal computers are generally limited to timescales up to the microsecond order in long-term studies, yet structural changes from fitting-induced fluctuations require calculations on the millisecond order. Due to its time-consuming nature, it is virtually impossible to simulate all processes involved in structural changes using only MD on common computers. For this reason, currently no high-accuracy methods are available for predicting the activated structure of GPCRs.

This paper describes a novel method to predict activated GPCR structures with high accuracy on standard workstations, while aiming for the use of the predicted 3D structures in *in silico* virtual screening in the future. First, we have developed a new method for modeling thermal fluctuations in GPCRs by using combinations of fluctuations with different time scales. Based on this model, we propose a novel computational method to search for one of the best 3D structures of an activated GPCR.

2. Model and Framework {#sec2}
======================

Proteins undergo thermal fluctuations of considerable magnitude. The time scale of thermal fluctuations in proteins ranges from femtoseconds to minutes, or even longer timescales \[[@B23]\]. In terms of spatial considerations, various levels of fluctuations exist, which include rapid motions within microspace (such as thermal oscillations between atoms and rotations of amino acid side chains), and relatively slow but large structural changes (such as local unfolding). Not all of these motions can be simulated because of the physical limits of currently available MD calculations. We therefore propose a new method for modeling GPCR thermal fluctuations, in which fluctuations are combined on different time scales. In this approach, we first simulate the oscillations and fluctuations of various atoms at the picosecond and nanosecond levels to obtain native structure within a short time span. We then simulate the thermal fluctuations of GPCRs in terms of their characteristic rotational motions around helical axes, which represent fluctuations of greater time scales. In our approach, some information on GPCRs that is known *a priori* is utilized. For instance, we know that TM helices are immobilized in a cell membrane, so their mobility is certainly low. Furthermore, this approach is based on the previous findings that when a GPCR is activated in a cell membrane, its structural changes occur by rotations around the axes of TM helices \[[@B24]\], and that especially TM3, TM5, and TM6 play an important role in the activation process in some GPCRs \[[@B18], [@B21]\]. Although this method does not guarantee the optimum from an exhaustive chemical calculation approach, it does have the clear advantage of reducing calculation load without sacrificing the quality of the solution obtained. We specifically focus on predicting the central part of the 7-TM helical bundle, a spacious ligand binding site, with good quality, while aiming for the use of the predicted 3D structures in *in silico* virtual screening in the future.

Based on this model, we propose a framework for structural search which comprises three stages, namely: (i) obtaining initial structures of a target GPCR by homology modeling using known GPCRs in their inactive forms as a template, (ii) obtaining average structures of a GPCR in a stable state after simulating fluctuations from several hundred picoseconds to a nanosecond using MD simulations, and (iii) obtaining a best 3D structure of a target GPCR in the active form through a machine-learning technique including evolutionary computation and modularized ligand-binding simulations. Our proposed method employs a real-coded genetic algorithm (GA) as an evolutionary computation to search appropriate rotation angles of helices of a target GPCR, in which discrete steps employ receptor-ligand docking simulations to evaluate the goodness of the rotation angles of the GPCR.

The core idea of the framework is that an MD simulation is used to calculate the 3D coordinates of all atoms of a target GPCR in a relaxed state in terms of heat fluctuation on the picosecond or nanosecond time scale, after which the evolutionary computation is used to determine the best ligand-bound rotation angles of helices of a GPCR as a movement on a longer time scale.

3. Methodology to Predict 3D Structure of Activated GPCR {#sec3}
========================================================

The detailed procedure of the proposed structural search method is described as follows.*Determination of an initial structure:* a known GPCR such as rhodopsin or beta-adrenergic receptor is used as a template. After alignment of the primary amino acid sequences of the template and target GPCR, the inactivated structure of the target GPCR is generated by regular homology modeling, which results in an initial structure.*Average molecular structures with respect to fluctuations on a short-time scale:* an appropriate amount of water molecules are added to the surroundings of the target GPCR. The fluctuations of GPCR molecules are then calculated by MD simulations at the level of several hundred picoseconds. The average structures are defined as those for which the energy values stabilize.*Structural changes with respect to rotational motions of helices:* hypothetical rotational motions around the axes of helices constituting the target GPCR (as fluctuations of greater-time scale) are generated. These are fed into a real-coded GA \[[@B25]\], as explained above, including simulations of binding with known ligands to determine optimal values. Details of the steps are described as follows. In addition, the schemes for generation alternation and offspring creation are shown in [Figure 1](#fig1){ref-type="fig"}.(3.1)*Generation of initial populations*. Individuals are assigned real-number vectors representing rotational angle changes relative to the average structures of various helices. These real-number vectors are treated as values within the space adjoining the two ends of the search space (i.e., toroidal space.) An initial population of *m* individuals is randomly generated.(3.2)*Creation of offspring for each generation*. Parents (two individuals) for random crossover of population pools are selected to match with a third parent, so as to generate offspring by the unimodal normal distribution crossover (UNDX) method \[[@B26]\]. The third parent is used to determine the standard deviation of normal distribution in UNDX. This procedure is repeated *n* times to provide *n* offspring individuals. In total, the number of individuals in a generation is *n* + 2 (offspring and two parents).(3.3)*Selection in each generation*. To evaluate each individual, receptor-ligand docking simulations are conducted using a known agonist and a known antagonist. An individual\'s real-valued vector translates into a corresponding 3D structure, with its side chains optimized before the binding simulations. An evaluation function has been established to represent how good the binding is. For a single individual, ligand-GPCR docking simulations are conducted up to *k* times, and each evaluation score is recorded. Upon obtaining the top score for each individual, the scores are then used to rank all individuals in a generation. The two individuals highest in ranking are selected (elite strategy) to replace the two parents in the population.(3.4)*Reiteration*. Steps (3.2) and (3.3) are repeated until some stop criteria are met.

The values for *m* and *n* can be determined based on previous researches and/or preliminary experiments. In our proposed search method, generation transition is achieved via the minimal generation gap (MGG) method \[[@B27]\]. MGG has good compatibility with UNDX and contributes to maintaining diversity in the population.

4. Test Case of Human Leukotriene B4 Receptor BLT1 {#sec4}
==================================================

This study reports on a novel approach to molecular modeling of 7-TM proteins that has been developed to build plausible active states of any given GPCR by using evolutionary computation. This heuristic approach starts from the amino-acid sequence of a target GPCR. We performed a validation test, where human leukotriene B4 receptor BLT1 was used as a sample target GPCR.

4.1. Leukotriene Receptor {#sec4.1}
-------------------------

Leukotriene (LT) is a bioactive lipid that serves as an important mediator of host defense, though it is also known to be implicated in bronchial asthma as a pathogenetic or precipitating factor. To date, four types of LT receptors have been cloned. One of these receptors, the high-affinity human LTB4 receptor BLT1 (GPCRDB entry ID: LT4R1_HUMAN; UniProt entry ID: Q15722), was selected as a target GPCR in our experiments. The length of the amino-acid sequence of BLT1 is 352aa.

4.2. Experimental Procedure {#sec4.2}
---------------------------

The sequence of BLT1 was retrieved from the UniProt database. ClustalX software \[[@B28]\] was used to align the sequence with the crystal structure of the bovine rhodopsin (UniProt entry ID: P02699) with which it shares a sequence similarity of more than 54%. One 3D structure of BLT1 obtained after running homology modeling using the bovine rhodopsin (PDB ID: 1L9H) as a template was selected from ModBase \[[@B29]\] as an initial rough 3D structure. ModBase is an open database of comparative protein structure models, theoretically calculated by the modeling pipeline ModPipe, which is maintained by Sali \[[@B30]\].

After annealing for atomic relaxation, MD simulations having distance restraints similar to a way proposed by Gouldson et al. \[[@B22]\] were run by using the TINKER software (ver. 4.2) \[[@B31]\]. The simulation conditions used were: force field = AMBER99; temperature = 310 K; pressure = 1 atm; time step = 1.0 fs. An average structure was determined after reaching a stable state, at which no steep drop in the molecular energy was observed. MD simulations for several hundred picoseconds were needed to achieve such a stable state.

The following are the processes of an evolutionary computation method in terms of optimizing the rotation angles of TM helices. The previous work performing amino-acid residue substitution analysis and spectroscopic experiments found that "TM3, TM5, and TM6 play an important role in activation of the leukotriene receptor \[[@B32]\]." This let us bound the free rotation space searched to these three helices; hence, the solutions we seek are the rotation angles of the three helices. Our proposed method employs a real-coded GA as a search algorithm and the ligand-binding simulation as an evaluation tool. An individual, which is defined as a real number vector representing the rotational angles of TM3, TM5, and TM6, has a unique value. In the evolutionary search process, the genetic operations mentioned in the previous section are repeated until the point when the stop criteria are met (the maximum generation number is 200, determined based on a preliminary experiment). The computational parameters in the evolutionary search are as follows: the initial population size is 50, and the number of offspring in a generation is 8. For evaluation of individuals, two sets of ligand-binding simulations are independently performed using a BLT1 agonist 12-keto-LTB4 (PubChem CID: 5280876) and a BLT1 antagonist pranlukast (PubChem CID: 115100). Docking of these ligands into the 3D structure of each individual, which is restored from the individual\'s vector representing the rotational angles of three helices to the 3D structure through structural relaxation by an *ab initio* (first-principle approach) computational method, is carried out with the GOLD software (ver. 3.1) \[[@B33]\]. The evaluation function in the evolutionary process is determined using the GOLD scores obtained from the docking simulations. The maximum GOLD scores derived from the docking with the BLT1 agonist and the BLT1 antagonist are assigned as *x* ~1~and *x* ~2~, respectively. The evaluation function value is shown below.

When *x* ~2~ \> 0, evaluation function value = *x* ~1~ − *x* ~2~; for all cases other than this condition, evaluation function value = *x* ~1~.

Finally, a best BLT1 structure obtained through the proposed method is evaluated by executing the docking simulations with many ligands other than ligands used in the evolutionary search process.

4.3. Results and Discussion {#sec4.3}
---------------------------

A computer with an Intel Xeon 3.6 GHz CPU (dual processor) was used for computation. For MD processing of 219.3-ps simulations, 524 hours were required. We investigated the changes in GPCR molecular energy values (kcal/mol) for every 0.1 ps time elapsed in MD, as shown in [Figure 2](#fig2){ref-type="fig"}. Lower-energy values suggest corresponding increases in structural stability. At the point of approximately 200 ps, energy values ceased to further fall, which suggests that a region of stability had been reached. As our study focused on MD simulations for structural changes on a short-time scale (meaning that the objectives were to simulate structural relaxation), we considered 200 ps to be a sufficient level and therefore stopped at 219.3 ps.

For subsequent evolutionary computation, 899 hours were required for calculations for 200 generations. [Figure 3](#fig3){ref-type="fig"} shows the trends of scores in evolutionary computation (the higher the scores, the better). The optimal solutions for rotational angles after 200 generations were: TM3 = 11°, TM5 = 14°, and TM6 = 255°.

[Figure 4](#fig4){ref-type="fig"} shows the state of binding between the LT receptor and its agonist in one of the best 3D structures computed. The 3D structures of binding are shown in [Figure 4(a)](#fig4){ref-type="fig"} with a view from above the cell plasma membrane and in [Figure 4(b)](#fig4){ref-type="fig"} with a cross-section of the membrane (the upper part being the extracellular space). In order to highlight receptor-ligand interactions, the main chains (backbones) of the helices are shown as ribbons, while the BLT1 agonist 12-keto-LTB4 is drawn as a ball-and-stick structure. From [Figure 4](#fig4){ref-type="fig"}, it is clear that the BLT1 agonist binds to a recessed region (pocket) formed by TM3, TM5, and TM6. Upon further analysis regarding the binding state of the LT receptor and its ligand, these helices responsible for interacting with the LT ligand are composed mostly of hydrophobic amino acid residues, suggesting that the BLT1 ligand is drawn into a strongly hydrophobic environment. Since the BLT1 agonist has many hydrophobic groups, it is likely that ligand-receptor binding is contributed to mainly by hydrophobic interactions, though several hydrogen bonding sites contribute to the binding. The following interactions are worth detailing.Hydrophobic interactions between TM3 and the alkyl side chain near the central carbonyl (--C=O) group of the BLT1 agonist.Hydrophobic interactions between TM5 and the alkyl side chain near the central carbonyl group of the BLT1 agonist.Hydrogen bonding between the --OH group in the carboxyl (--COOH) group of the BLT1 ligand and the carbonyl group of Asn241 on TM6 (C=O⋯H--O intermolecular distance 2.32 Å.).Hydrogen bonding between the central carbonyl group of the BLT1 agonist and the main chain (--N--H peptide bond) of Gly246 on the loop joining TM6 and TM7 (C=O⋯H--O intermolecular distance 2.13 Å.).Hydrophobic interactions between TM6 and all alkyl side chains of the BLT1 agonist.In addition to TM3, TM5, and TM6, we speculate that TM7 also contributes to hydrophobic interactions with the alkyl side chains of the BLT1 agonist.

At the beginning of evaluation, we calculated the root mean square deviation (RMSD) of BLT1 structures to investigate the structure change. Firstly, we obtained initial structures from homology modeling as structure I, MD relaxed structures as structure II, and structures generated from post-MD evolutionary computation as structure III to calculate the RMSD of 1,316 atoms forming the backbones. The resultant RMSDs were 4.49 Å for structures I and II, 1.55 Å for structures II and III, and 4.63 Å for structures I and III. Based on these values, the transition from structure I to structure II involved a large change. The reason why the transition from structure II to structure III was a smaller change is that the evolutionary search process only altered the rotation angle of TM3, TM5, and TM6. Nevertheless, what is interesting is that in the transition from structure II to structure III, the amount of rotational angle change in TM6 was clearly large compared with the other two TM helices: TM3 = 11°, TM5 = 14°, and TM6 = 255°. This is consistent with other previous research showing that the TM6 region plays a very important role in the transition from inactive-state to active-state rhodopsin \[[@B34]\]. Since GPCRs including the leukotriene receptor are allosteric proteins, the conformational change from inactive to active state likely affects the state of engagement with the associated G-protein. However, details of this mechanism require additional research.

In order to check the validity of LT receptor structures obtained by our method, we further used 6 known BLT1 agonists (including 12-keto-LTB4) and 14 known BLT1 antagonists (including pranlukast) to independently perform binding simulations with BLT1 of the optimal 3D structure, from which the corresponding maximum GOLD scores were determined. The results are as shown in [Figure 5](#fig5){ref-type="fig"} such that the agonists and antagonists are plotted in order of decreasing scores. The agonist group produced scores that were visibly higher than those of the antagonist group. By using the Wilcoxon signed rank test (which makes no assumptions on normality of distribution), the GOLD scores of the agonist group and the antagonist group were found to be significantly different (*P* = 0.00046). This strongly suggests that the binding pocket obtained by our search method selectively binds with the BLT1 agonists.

Next, in order to assess the quality of the agonist binding states, we have challenged the best 3D structure model with a set of 144 GPCR ligands to determine whether the structure indeed shows a good preference for BLT1 agonists. The ligand set included 6 BLT1 agonists (including 12-keto-LTB4), 14 BLT1 antagonists (including pranlukast), and 124 other GPCR ligands (32 against serotonin receptors, 17 against histamine receptors, 17 against adenosine receptors, 14 against prostanoid receptors, 10 against dopamine receptor, 8 against adrenoceptors, 8 against angiotensin receptors, 7 against cannabinoid receptors, and 11 against other GPCRs), as shown in [Table 1](#tab1){ref-type="table"}. Being GPCR ligands, these ligands automatically have "drug-like" properties, so the only filtering on the ligand selection was to ensure that BLT1- and non-BLT1 ligands had a similar molecular mass distribution. The ligand-binding simulations were individually performed using the GOLD software. The overall docking results for the most highly ranked conformations are shown in [Figure 6](#fig6){ref-type="fig"}. Based on the GOLD binding score (higher indicates better binding), all 6 BLT1 agonists were ranked in the top 11. The enrichment curve in [Figure 6](#fig6){ref-type="fig"} shows that there is immediate enrichment, and the results are good compared to related studies \[[@B22], [@B35]\]. This also suggests that the binding pocket obtained by our search method selectively binds with the BLT1 agonists.

Consequently, we have developed a search method capable of predicting the 3D structures of active forms of GPCRs, which is broadly consistent with known facts of the target proteins and is reasonably persuasive as a model.

5. Discussion and Conclusions {#sec5}
=============================

With no crystal structures of active-state GPCRs other than mutant rhodopsin \[[@B34]\], it is indispensable to develop a practical method to predict 3D structures of activated GPCRs from their sequence information. In this study, we proposed a method for finding one of the best structures of an activated GPCR at a level of accuracy acceptable to virtual screening. The method was validated using human leukotriene B4 receptor BLT1 as a sample GPCR. Our study demonstrated that the proposed method including homology modeling, MD simulations, and evolutionary computing was able to provide the appropriate 3D structure of the activated leukotriene receptor to specifically dock with its agonists.

The first remarkable feature of this study is that the proposed method models GPCR thermal fluctuations on multiple time scales: the short-term heat fluctuation on the picosecond or nanosecond time scale and the rotational motions of TM helices on a longer time scale. This is a kind of coarse approximation compared with other methods like rigorous long-term MD simulations. However, the proposed method provides a significant reduction in computational cost when predicting the 3D structure of GPCRs and finally leads us to obtain the structure on common personal computers.

The second feature is that a machine learning technique including evolutionary computation and modularized ligand-binding simulations is employed for the structural prediction. Though to date, there have been methods using GAs to generate various conformations of ligands to explore a most suitable conformation in ligand-receptor docking \[[@B36]\], our method is the first approach using a GA employing a modularized ligand-binding simulation to find a best conformation on the receptor side.

However, some improvements might remain in the evaluation function of our evolutionary computing. Essentially, a scoring system capable of closely reflecting the binding-free energy would be desirable for the conformation evaluation. In our method, the GOLD scores produced by the GOLD software are directly used for the evaluation function. Although the GOLD scores are related with the values of the binding-free energy, they are not identical. We should accordingly investigate this issue in the future.

In addition, it should be noted that our method has a tendency to predict the central part of the 7-TM helical bundle, a spacious ligand binding site, with good quality. That is, small deviations would be observed in a spacious binding pocket area, whereas larger deviations would be observed in the distal section of the helices and even larger in the loop regions. This is because the evaluation function in evolutionary computing is naturally based on the ligand-binding score, closely related with the binding free energy. Hence, our method may predict another structure having energetically highly evaluated conformations of seven helices and the loops as a best structure if another search is performed. However, the structure of the spacious ligand-binding site would emerge again. We originally have the purpose of using the predicted 3D structure for virtual screening of candidate chemicals. Our method is able to provide 3D structure accurately enough for this purpose as shown in the case of the leukotriene receptor, since the structural information of the spacious binding pocket area is the most important for virtual screening.

We anticipate that parallelization of the proposed algorithm would contribute to an improvement in computation time. Future study designs will incorporate such. Furthermore, we plan to use GPCRs other than the leukotriene receptor to test the applicability and robustness of our search method. For such investigations, it would be important to carefully select an appropriate target GPCR. Based on sequence similarity within the seven TMs, GPCRs can be grouped into six families: the rhodopsin family A, the secretin family B, the glutamate receptor family C, the fungal pheromone family D, the cAMP receptor family E, and the frizzled/smoothened receptor family F \[[@B37]\]. In general, GPCRs belonging to class A fit the prediction, because all known GPCRs used as templates in homology modeling are classified into the class A. In contrast, other GPCRs having low amino-acid homology would need extra processing at the preliminary stage of homology modeling.
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![Ligand-receptor docking score (GOLD score) when docking with known agonists and antagonists of BLT1. Open squares show docking scores of known BLT1 agonists. Filled triangles show docking scores of known BLT1 antagonists. PubChem ID of BLT1 agonists (descending order): 5280492, 5280745, 5283156, 5280876, 5283129, 5280877. PubChem ID of BLT1 antagonists (descending order): 159476, 3081307, 6444688, 6439064, 6449854, 6540750, 132425, 6439436, 115100, 6442838, 204055, 177941, 196905, 192617.](TSWJ2012-691579.005){#fig5}

![Enrichment curve for various GPCR ligands docked into the predicted active-state BLT1 structure.](TSWJ2012-691579.006){#fig6}

###### 

Ligands used for evaluation.

  No.   PubChem ID   Receptor name                    Ligand       GLIDA ID   Molecular weight
  ----- ------------ -------------------------------- ------------ ---------- ------------------
  1     5280492      Leukotriene receptor             Agonist      L000354    336
  2     5280745      Leukotriene receptor             Agonist      L000056    352
  3     5283156      Leukotriene receptor             Agonist      L000050    320
  4     5280876      Leukotriene receptor             Agonist      L000049    334
  5     5283129      Leukotriene receptor             Agonist                 336
  6     5280877      Leukotriene receptor             Agonist      L000055    366
  7     159476       Leukotriene receptor             Antagonist   L001349    304
  8     3081307      Leukotriene receptor             Antagonist   L011298    414
  9     6444688      Leukotriene receptor             Antagonist   L002037    502
  10    6439064      Leukotriene receptor             Antagonist   L002263    360
  11    6449854      Leukotriene receptor             Antagonist   L000610    361
  12    6540750      Leukotriene receptor             Antagonist   L015882    346
  13    132425       Leukotriene receptor             Antagonist   L006854    358
  14    6439436      Leukotriene receptor             Antagonist   L009515    536
  15    115100       Leukotriene receptor             Antagonist   L000493    481
  16    6442838      Leukotriene receptor             Antagonist   L001488    455
  17    204055       Leukotriene receptor             Antagonist   L006005    537
  18    177941       Leukotriene receptor             Antagonist   L001468    544
  19    196905       Leukotriene receptor             Antagonist   L006944    539
  20    192617       Leukotriene receptor             Antagonist   L011726    600
  21    68555        Dopamine receptor                Agonist      L013392    307
  22    55483        Dopamine receptor                Agonist      L013398    356
  23    5760         Dopamine receptor                Agonist      L000836    303
  24    3341         Dopamine receptor                Agonist      L000254    306
  25    5281878      Dopamine receptor                Antagonist   L000188    434
  26    4748         Dopamine receptor                Antagonist   L000919    403
  27    28864        Dopamine receptor                Antagonist   L000349    338
  28    5265         Dopamine receptor                Antagonist   L000569    395
  29    2818         Dopamine receptor                Antagonist   L000195    327
  30    5074         Dopamine receptor                Antagonist   L001003    477
  31    4038180      Adrenoceptors                    Agonist      L000090    309
  32    3251         Adrenoceptors                    Agonist      L000768    581
  33    13109        Adrenoceptors                    Agonist      L000895    312
  34    2419         Adrenoceptors                    Antagonist   L000137    385
  35    3372         Adrenoceptors                    Antagonist   L000257    437
  36    5640         Adrenoceptors                    Antagonist   L000080    401
  37    47811        Adrenoceptors                    Antagonist   L000474    314
  38    2369         Adrenoceptors                    Antagonist   L000125    307
  39    2790         Histamine receptor               Antagonist   L000192    308
  40    55482        Histamine receptor               Antagonist   L000593    441
  41    41376        Histamine receptor               Antagonist   L000313    321
  42    3219         Histamine receptor               Antagonist   L001093    302
  43    5533         Histamine receptor               Antagonist   L000771    371
  44    65895        Histamine receptor               Antagonist   L000115    380
  45    3947         Histamine receptor               Antagonist   L000944    418
  46    2678         Histamine receptor               Antagonist   L000655    388
  47    3957         Histamine receptor               Antagonist   L000667    382
  48    2342         Histamine receptor               Antagonist   L000844    404
  49    4830         Histamine receptor               Antagonist   L000727    375
  50    475096       Histamine receptor               Antagonist   L000558    440
  51    4940         Histamine receptor               Antagonist   L000807    340
  52    4066         Histamine receptor               Antagonist   L000704    322
  53    3348         Histamine receptor               Antagonist   L000869    501
  54    124488       Histamine receptor               Antagonist   L001444    608
  55    5282450      Histamine receptor               Antagonist   L001378    392
  56    132059       Serotonin receptor               Agonist      L000336    411
  57    127728       Serotonin receptor               Agonist      L000873    465
  58    197706       Serotonin receptor               Agonist      L000746    403
  59    57347        Serotonin receptor               Agonist      L000797    415
  60    219050       Serotonin receptor               Agonist      L001062    346
  61    3408722      Serotonin receptor               Agonist      L000428    365
  62    4440         Serotonin receptor               Agonist      L000432    335
  63    56971        Serotonin receptor               Agonist      L000682    401
  64    91273        Serotonin receptor               Agonist      L000863    383
  65    71351        Serotonin receptor               Agonist      L001106    420
  66    5311258      Serotonin receptor               Agonist      L000364    351
  67    5761         Serotonin receptor               Agonist      L000352    323
  68    5311097      Serotonin receptor               Agonist      L000365    351
  69    37816        Serotonin receptor               Agonist      L000794    340
  70    3292447      Serotonin receptor               Agonist      L001346    486
  71    16362        Serotonin receptor               Antagonist   L000494    461
  72    3559         Serotonin receptor               Antagonist   L000288    375
  73    55216        Serotonin receptor               Antagonist   L000503    346
  74    4431         Serotonin receptor               Antagonist   L000685    393
  75    5073         Serotonin receptor               Antagonist   L000510    410
  76    2726         Serotonin receptor               Antagonist   L000182    318
  77    55752        Serotonin receptor               Antagonist   L000720    440
  78    5684         Serotonin receptor               Antagonist   L000012    422
  79    28693        Serotonin receptor               Antagonist   L000396    403
  80    4106         Serotonin receptor               Antagonist   L000397    356
  81    68848        Serotonin receptor               Antagonist   L000394    362
  82    37459        Serotonin receptor               Antagonist   L000016    361
  83    107780       Serotonin receptor               Antagonist   L000275    497
  84    3378093      Serotonin receptor               Antagonist   L000538    520
  85    1229         Serotonin receptor               Agonist      L000011    321
  86    3654103      Serotonin receptor               Agonist      L000142    406
  87    4585         Serotonin receptor               Antagonist   L000455    312
  88    133083       Angiotensin receptor             Antagonist   L008043    490
  89    114899       Angiotensin receptor             Antagonist   L000467    480
  90    3749         Angiotensin receptor             Antagonist   L000319    428
  91    60921        Angiotensin receptor             Antagonist   L000533    610
  92    2541         Angiotensin receptor             Antagonist   L000156    440
  93    5281037      Angiotensin receptor             Antagonist   L000248    424
  94    60846        Angiotensin receptor             Antagonist   L000621    435
  95    5833         Angiotensin receptor             Antagonist   L001221    416
  96    472880       Follicle stimulating hormone     Agonist      L000979    352
  97    125672       Melanocortin hormone             Agonist      L000639    342
  98    6434259      Prostanoid receptor              Agonist      L000194    424
  99    6436393      Prostanoid receptor              Agonist      L000160    350
  100   5311027      Prostanoid receptor              Agonist      L001211    415
  101   5311503      Prostanoid receptor              Agonist      L000634    384
  102   119304       Prostanoid receptor              Agonist      L000151    368
  103   5311493      Prostanoid receptor              Agonist      L024041    350
  104   6433212      Prostanoid receptor              Agonist      L000478    354
  105   6439022      Prostanoid receptor              Agonist      L000570    362
  106   122021       Prostanoid receptor              Antagonist   L000153    459
  107   160          Prostanoid receptor              Antagonist   L000705    354
  108   5311213      Prostanoid receptor              Antagonist   L024043    442
  109   50294        Prostanoid receptor              Antagonist   L001326    371
  110   132836       Prostanoid receptor              Agonist      L000098    388
  111   5311035      Prostanoid receptor              Agonist      L000150    408
  112   164437       Adenosine receptor               Agonist      L000290    388
  113   104795       Adenosine receptor               Agonist      L000437    308
  114   164305       Adenosine receptor               Agonist      L001390    363
  115   93205        Adenosine receptor               Agonist      L000708    385
  116   123807       Adenosine receptor               Agonist      L000165    369
  117   3086599      Adenosine receptor               Agonist      L001283    499
  118   5311506      Adenosine receptor               Antagonist   L000893    337
  119   1329         Adenosine receptor               Antagonist   L000233    304
  120   393595       Adenosine receptor               Antagonist   L000629    403
  121   176408       Adenosine receptor               Antagonist   L000548    345
  122   5697         Adenosine receptor               Antagonist   L000963    428
  123   64627        Adenosine receptor               Antagonist   L001406    356
  124   1970         Adenosine receptor               Agonist      L001216    399
  125   9576912      Adenosine receptor               Agonist      L001516    393
  126   122246       Adenosine receptor               Agonist      L000951    521
  127   5287468      Adenosine receptor               Agonist      L000058    526
  128   123739       Adenosine receptor               Antagonist   L001123    386
  129   16078        Cannabinoid receptor             Agonist      L000023    314
  130   5281969      Cannabinoid receptor             Agonist      L000111    347
  131   5689         Cannabinoid receptor             Agonist      L000626    426
  132   5488671      Cannabinoid receptor             Agonist      L000222    395
  133   104895       Cannabinoid receptor             Agonist      L000004    376
  134   39860        Cannabinoid receptor             Agonist      L000994    372
  135   5311257      Cannabinoid receptor             Antagonist   L000363    383
  136   4172142      Melatonin receptor               Agonist      L000306    348
  137   4004         Melatonin receptor               Antagonist   L001138    330
  138   5311198      Melatonin receptor               Antagonist   L000326    376
  139   6024         Calcitonin receptor              Agonist      L000905    396
  140   91498        Calcitonin receptor              Agonist      L024117    421
  141   446284       Metabotropic glutamate group I   Agonist      L001256    302
  142   6324636      Metabotropic glutamate group I   Antagonist   L000366    323
  143   5311262      Metabotropic glutamate group I   Antagonist   L000372    383
  144   123885       GABA-B subtype 1                 Antagonist   L000172    401

[^1]: Academic Editors: S. Jahandideh, P. Jain, and M. Liu
